cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
cabazitaxel teva
teva b.v. - cabazitaxel - prostatické nádory - antineoplastické činidlá - liečba rakoviny prostaty.
cabazitaxel ever pharma 10 mg/ml koncentrát na infúzny roztok
ever valinject gmbh, rakúsko - kabazitaxel - 44 - cytostatica
cabazitaxel msn
msn labs europe limited, malta - kabazitaxel - 44 - cytostatica
cabazitaxel fresenius kabi 20 mg/ml
fresenius kabi s.r.o., Česká republika - kabazitaxel - 44 - cytostatica
jevtana
sanofi winthrop industrie - cabazitaxel - prostatické nádory - antineoplastické činidlá - jevtana v kombinácii s prednizónom alebo prednizolónom je indikovaná na liečbu pacientov s metastatickým karcinómom prostaty refraktérneho pôvodu, ktorý bol predtým liecený režimom obsahujúcim docetaxel.
eleber 60 mg koncentrát a rozpúšťadlo na infúzny roztok
zentiva, k.s., Česká republika - kabazitaxel - 44 - cytostatica
xtandi
astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
enzalutamid sandoz 80 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - enzalutamid - 44 - cytostatica
enzalutamid sandoz 40 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - enzalutamid - 44 - cytostatica